Working... Menu

An Extension Study to Assess the Long-term Safety and Efficacy of Pasireotide in Patients With Acromegaly

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00171730
Recruitment Status : Completed
First Posted : September 15, 2005
Last Update Posted : November 16, 2016
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
Acromegaly is a rare, serious condition characterized by chronic hypersecretion of growth hormone (GH), generally caused by a GH-secreting pituitary adenoma. This study will assess the long-term safety and efficacy of pasireotide in patients with acromegaly.

Condition or disease Intervention/treatment Phase
Acromegaly Drug: Pasireotide Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Extension to a Multi-center, Randomized, Crossover, Open Label, Dose Finding Study to Compare the Safety, Efficacy, and Pharmacokinetics/Pharmacodynamics (PK/PD) Relationship of Multiple Doses of Pasireotide (SOM230) (200, 400, and 600 μg Bid) and Doses of Open Label Sandostatin® (SMS) (100 μg Tid) in Acromegalic Patients
Study Start Date : August 2004
Actual Primary Completion Date : December 2013
Actual Study Completion Date : December 2013

Resource links provided by the National Library of Medicine

Drug Information available for: Pasireotide

Arm Intervention/treatment
Experimental: Pasireotide s.c. (SOM230) Drug: Pasireotide

Primary Outcome Measures :
  1. Circulating GH- and IGF-1 concentrations measured every 4 weeks [ Time Frame: Every 6 months ]

Secondary Outcome Measures :
  1. Long-term safety and efficacy of multiple doses of Pasireotide s.c. [ Time Frame: Every 3 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients who have completed all four treatment regimens in the core study CSOM230B2201 and achieved biochemical control in GH and IGF-1 levels after at least one month of pasireotide administration at any of the three doses
  • Patients who did not experience any unacceptable adverse events or tolerability issues during the core study CSOM230B2201

Exclusion Criteria:

  • Patients who experienced or developed compression of the optic chiasm causing any visual field defect during the core study CSOM230B2201
  • Patients who required a surgical intervention for relief of any sign or symptom associated with tumor compression during the core study CSOM230B2201 Patients who experienced or developed congestive heart failure, unstable angina, sustained ventricular tachycardia, ventricular fibrillation or acute myocardial infraction during the core study CSOM230B2201

Other protocol-defined inclusion/exclusion criteria may apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00171730

Layout table for location information
United States, California
Cedars Sinai Medical Center Dept. of Pituitary Ctr.
Los Angeles, California, United States, 90048
United States, Michigan
University of Michigan Health System StudyCoordinatorCSOM230B2201E1
Ann Arbor, Michigan, United States, 48109
United States, New York
NYU / VA Medical Center
New York, New York, United States, 10010
Australia, Queensland
Novartis Investigative Site
Woolloongabba, Queensland, Australia, 4102
Novartis Investigative Site
Edegem, Belgium, 2650
Novartis Investigative Site
Toulouse Cédex 4, France, 31043
Novartis Investigative Site
Essen, Germany, 45122
Novartis Investigative Site
Muenchen, Germany, 80336
Novartis Investigative Site
Napoli, Italy, 80131
Novartis Investigative Site
Lausanne, Switzerland, 1011
Sponsors and Collaborators
Novartis Pharmaceuticals
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Study Chair: Novartis Novartis

Additional Information:
Publications of Results:
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals Identifier: NCT00171730     History of Changes
Other Study ID Numbers: CSOM230B2201E1
2004-002849-12 ( EudraCT Number )
First Posted: September 15, 2005    Key Record Dates
Last Update Posted: November 16, 2016
Last Verified: November 2016

Keywords provided by Novartis ( Novartis Pharmaceuticals ):

Additional relevant MeSH terms:
Layout table for MeSH terms
Bone Diseases, Endocrine
Bone Diseases
Musculoskeletal Diseases
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs